RECRUITING

Depo-Medrol on Psoas After LLIF

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

Official Title

Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness

Quick Facts

Study Start:2023-05-12
Study Completion:2027-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05929755

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients from the practices of Drs. Singh, Mallozzi, Moss
  2. * Transpsoas (PTP or LTP) lateral lumbar interbody fusion (LLIF) 1-3 disc levels with posterior instrumentation (Open or MIS) with or without laminectomy, must include L3-4 and/or L4-5
  3. * Patients who agree to be a part of the study
  4. * Patients with lumbar disc degeneration
  5. * Patients between ages of 18 and 75
  1. * Scoliosis \>10°
  2. * Spondylolisthesis \>Grade 1
  3. * Flatback deformity
  4. * Patients with insulin dependent diabetes
  5. * Patients with \>3 levels of fusion
  6. * Alternative interbodies
  7. * Chronic oral steroid users
  8. * Patients with allergy/intolerance to depo-medrol or other steroids
  9. * Patients requiring bilateral transpsoas approaches
  10. * Patients with ipsilateral symptomatic hip pathology
  11. * Revision fusion procedures
  12. * Cases involving trauma, tumor, or infection
  13. * Patient's not capable of providing consent themselves
  14. * Non-fluent English speakers (for consenting reasons)
  15. * Patients who are lost to follow-up before the two year follow up period

Contacts and Locations

Study Contact

Hardeep Singh, MD
CONTACT
860-679-6883
uconnorthopaedics@uchc.edu
Study Coordinator
CONTACT
860-679-6883
uconnorthopaedics@uchc.edu

Principal Investigator

Hardeep Singh, M.D.
PRINCIPAL_INVESTIGATOR
UConn Health

Study Locations (Sites)

UConn Health
Farmington, Connecticut, 06030
United States

Collaborators and Investigators

Sponsor: Hardeep Singh

  • Hardeep Singh, M.D., PRINCIPAL_INVESTIGATOR, UConn Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-12
Study Completion Date2027-05

Study Record Updates

Study Start Date2023-05-12
Study Completion Date2027-05

Terms related to this study

Keywords Provided by Researchers

  • lateral lumbar interbody fusion
  • LLIF
  • Depo-Medrol
  • corticosteroid
  • lumbar spine
  • psoas muscle
  • postoperative hip flexor weakness
  • postoperative thigh pain
  • postoperative thigh numbness

Additional Relevant MeSH Terms

  • Muscle Weakness
  • Pain, Postoperative
  • Paresthesia
  • Pain, Muscle